A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/41 (2006.01) A61K 31/122 (2006.01) A61K 31/4015 (2006.01) A61K 31/4025 (2006.01) A61K 31/557 (2006.01) A61K 31/5575 (2006.01) A61K 31/559 (2006.01) A61K 45/06 (2006.01) A61P 27/06 (2006.01) A61K 9/00 (2006.01)
Patent
CA 2466757
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
L'invention concerne des agonistes sélectifs puissants du sous-type EP¿4? de récepteurs de la prostaglandine E2, l'utilisation de ceux-ci ou une formulation de ceux-ci dans le traitement du glaucome et d'autres états relatifs à une pression intraoculaire élevée dans l'oeil d'un patient. L'invention concerne également l'utilisation de tels composés permettant de conférer un effet neuroprotecteur à l'oeil d'espèces mammifères, notamment les êtres humains.
Billot Xavier
Metters Kathleen Mary
Ogidigben Miller J.
Slipetz Deborah M.
Young Robert N.
Merck & Co. Inc.
Merck Frosst Canada & Co./merck Frosst Canada & Cie
Merck Frosst Canada Ltd.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Method for treating ocular hypertension does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating ocular hypertension, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating ocular hypertension will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1478582